Addendum

Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76

Status
Status: Commission completed
Project no.
A23-132
Last updated

Report documents

  1. Addendum

    Mavacamten (obstructive hypertrophic cardiomyopathy) – Addendum to Project A23-76

    published on
    Document type
    PDF document, 495 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-132_en

Dossier assessment

Indication:

Adult patients with symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM)

Result of dossier assessment:

After addendum now: hint of considerable added benefit

Press releases

Considerable added benefit of mavacamten in obstructive hypertrophic cardiomyopathy

Due to unclear and missing information in the dossier, it had not yet been possible to prove an added benefit in a dossier assessment in 2023. The drug manufacturer provided additional data in the commenting procedure – with a positive result.

Additional information

Federal Joint Committee (G-BA)

2024-02-01 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-132
Commission
Commission awarded on 12.12.2023 by the Federal Joint Committee (GBA).
Report type
Addendum
Status
Commission completed
Department/Division
Drug Assessment
Topic
Heart and circulation
Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://dx.doi.org/10.60584/A23-132_en

Connected Projects

  1. Dossier assessment

    Mavacamten (cardiomyopathy) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-76
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form